null

Recombinant Mouse Leukocyte Ig-Like Receptor B4/LILRB4/CD85k/ILT3 (C-Fc) (RPES6629)

SKU:
RPES6629
Product Type:
Recombinant Protein
Species:
Mouse
€199

Description

Product Name:Recombinant Mouse Leukocyte Ig-Like Receptor B4/LILRB4/CD85k/ILT3 (C-Fc)
Product Code:RPES6629
Size:10µg
Species:Mouse
Expression Host:HEK293 Cells
Synonyms:Leukocyte immunoglobulin-like receptor subfamily B member 4, Mast cell surface glycoprotein Gp49B, CD85k, Lilrb4, Gp49b
Mol Mass:51 kDa
AP Mol Mass:65-85 kDa
Tag:C-Fc
Purity:> 95 % as determined by reducing SDS-PAGE.
Endotoxin Level:< 1.0 EU per μg of the protein as determined by the LAL method.
Bio Activity:Testing in progress
Sequence:Gly24-Lys238
Accession:Q64281
Storage:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping:This product is provided as lyophilized powder which is shipped with ice packs.
Formulation:Lyophilized from a 0.2 μm filtered solution of 50 mM Tris-HCl, 100mM Glycine, pH 7.5. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the p
Reconstitution:Please refer to the printed manual for detailed information.
Background:Mouse Leukocyte Immunoglobulin-like Receptor Subfamily B Member 4 (LILRB4/CD85k/ILT3) is an approximately transmembrane glycoprotein that negatively regulates immune cell activation. Mouse LILRB4 consists of a 215 amino acid (aa) extracellular domain with two Ig-like domains, a 22 aa transmembrane segment, and a 75 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM). Within the ECD, mouse LILRB4 shares 45% and 77% aa sequence identity with human and rat LILRB4, respectively. Alternative splicing of mouse LILRB4 generates a potentially soluble isoform that lacks the transmembrane segment. LILRB4 is expressed on dendritic cells (DC), monocytes, macrophages, and vascular endothelial cells (EC). Ligation of LILRB4 triggers ITIM-mediated inhibition of cellactivating signaling, leading to enhanced immune tolerance and reduced allogeneic graft rejection. Soluble LILRB4 induces the differentiation of CD8+ T suppressor cells (Ts) that can inhibit the effector functions of CD4+ Th cells and CD8+ CTL. In turn, CD8+ Ts cells induce LILRB4 up-regulation and a tolerogenic phenotype in monocytes, DC, and EC.

Related Products